Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
"We are now embarking on a new Long March, and we must start all over again!" Xi Jinping said.Marketsread more
CBS plans to renew discussions for Starz with Lions Gate in the coming weeks, according to people familiar with the matter. If a deal happens, the remainder of Lions Gate...Technologyread more
The launch comes as Apple's laptops have been criticized for a keyboard that users say breaks easily and results in key presses that cause characters to double up or not...Tech Driversread more
Craig Irwin of Roth Capital Partners said Apple tried to buy Tesla six years ago for a higher price than where the stock now trades.Technologyread more
The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
Connecticut state Sen. Alex Bergstein's divorce case with her husband, Morgan Stanley managing director Seth Bergstein, has exposed her new romantic relationship with her...Politicsread more
Donaldson was chief of staff to former White House counsel Don McGahn, who on Tuesday defied the Judiciary panel's subpoena to testify about special counsel Robert Mueller's...Politicsread more
As shopping has shifted online and styles have evolved, Ascena has been grappling with sagging sales and a large debt-load. Looking to stem the losses, Ascena is turning to...Retailread more
The U.S. State Department's current offer is the final one, according to multiple sources.Politicsread more
Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of pharmaceutical giant Pfizer is having an impact on how other companies in health care set their prices.
“By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said in an exclusive video for CNBC PRO. “Even if they maybe raise prices in a different way – if they typically raise prices in a different way or do it on a different subset of products, they’re going to be thinking twice.”
The investor’s comments came less than 10 days after Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies . For its part, Pfizer raised the price of 41 drugs by as much as 9 percent, though it also lowered prices on five drugs by as much as 44 percent.
In a statement, Pfizer defended itself and argued that the price adjustments only affected a minor portion of the company’s extensive portfolio of treatments. The company's stock fell 0.2 percent Monday, but is up 2.9 percent since January; is up 5 percent year to date.
"Our portfolio includes more than 400 medicines and vaccines; we are modifying prices for approximately 10 percent of these, including some instances where we’re decreasing the price," Pfizer said in a statement. "Importantly, list prices do not reflect what most patients or insurance companies pay.”
Denner, a Carl Icahn protege, is known for his shareholder activism in the biotechnology and pharmaceutical industries. Through Sarissa, he currently has active stakes in Biogen, Ironwood Pharmaceuticals and The Medicines Company.
Sarissa oversees $535 million in assets under management according to its latest Form ADV filing.
Click here to see the full video, but you must be a CNBC Pro subscriber.